Maltose

Summary

Maltose (CHEMBL1908365) is a phase-3 clinical-stage oligosaccharide geroprotector; indicated across 3 conditions including bipolar disorder and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 342.3 Da · C12H22O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908365
Name	Maltose
Type	Oligosaccharide
Max phase	3
FDA approved	no
PubChem CID	6255
ChEBI	CHEBI:18147
Molecular formula	C12H22O11
Molecular weight	342.3
InChIKey	GUBGYTABKSRVRQ-QUYVBRFLSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O

IUPAC name: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol

ChEBI definition: A maltose that has β-configuration at the reducing end anomeric centre.

Pharmacological roles (ChEBI): geroprotector.

Also known as: Maltose, Maltose anhydrous, unspecified form, NSC-760396, MALTOSE, D-(+)-MALTOSE

Patent coverage: 146,177 distinct patent families (409,301 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bipolar disorder	3	MONDO:0004985	MONDO:0004985
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	4
PHASE2	2
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02800161	PHASE3	COMPLETED	Trehalose as add-on Therapy in Bipolar Depression
NCT01146535	PHASE2	COMPLETED	Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
NCT06196450	PHASE2	UNKNOWN	Maternal Probiotic Intervention to Improve Gut Health
NCT02903030	EARLY_PHASE1	COMPLETED	Probiotics for Quality of Life in Autism Spectrum Disorders
NCT05920018	Not specified	RECRUITING	Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis
NCT06133530	Not specified	ENROLLING_BY_INVITATION	Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica
NCT04399265	Not specified	UNKNOWN	Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
NCT04505800	Not specified	COMPLETED	Tryptophan Supplementation to Improve Night Shift Workers’ Health

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).